Kristoffer from Sweden

Registered at the short selling broker eToro, 2 minutes ago.

» Try eToro you too
75% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Merck & Co., Inc. (MRK) shares information

Merck & Co Inc


24h Change

-0.88 %

MRK

Live rate: Market closed

Stock data per Wednesday 20 Jan, 2021

MRK
NEW YORK STOCK EXCHANGE, INC.
83.19
83.25
82.46
-0.73 (-0.88%)
US Market is closed

Live Stock price in graph for Merck & Co Inc (MRK)

  • Latest Volume

    10,585,340 (31.02 %)

  • Volume prev. day

    8,079,485

  • Avg. daily volume

    8,257,386

  • Market cap

    208,626,639,675

  • P/E ratio

    18.2

  • Today high

    83.55 USD

  • Today low

    82.265 USD

  • 52 week high

    86.89 USD

  • 52 week low

    64.89 USD

  • YTD Change

    + 0.82 %

Quick links

 

Latest news about Merck & Co Inc

Below you can find the most recent news posts about Merck & Co Inc, primarily from US and UK based news sources.

Supreme Court Rejects Merck’s Bid to Reinstate $2.5B Damage Award Against Rival

Wednesday, 20 January 2021, 17:09:53
The U.S. Supreme Court on Tuesday rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment. …
— Insurance Journal


Merck KGaA, Darmstadt, Germany Announces Update on the [email protected] Clinical Program Including Lung 037 Study

Wednesday, 20 January 2021, 16:04:00
DARMSTADT, Germany, Jan. 20, 2021 /PRNewswire/ — Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III [email protected] Lung 037 study and the extensive [email protected] clinical trial program for the…
— PR Newswire


Merck KGaA, GSK Suffer Lung Cancer Drug Setback

Wednesday, 20 January 2021, 15:27:31
Merck KGaA's drug development programme has suffered a setback with the most important clinical trial of its cancer drug hopeful bintrafusp alfa stopped because the treatment does not appear to work.
— CNN-News18


GlaxoSmithKline's $4B bispecific cancer drug alliance with Merck KGaA hits a setback with a trial flop for NSCLC

Wednesday, 20 January 2021, 14:48:37
Close to 2 years ago, GSK’s R&D team eagerly agreed to pay up to $4 billion-plus to ally itself with Merck KGaA on a mid-stage bispecific called bintrafusp alfa, which intrigued them with the combination of a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein. But today the
— Endpoints News


Merck makes good on big CV gamble with vericiguat nod — but competition will be fierce

Wednesday, 20 January 2021, 13:15:14
The results for Merck's leading heart drug fell short of what some cardiologists had hoped for, but they proved more than enough to convince the FDA, which handed down an approval Wednesday. The agency OK'd vericiguat, now marketed as Verquvo, for patients with heart failure, offering one of the first
— Endpoints News


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €200
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have MRK available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.